LT3348546T - Androgeno receptorių inhibitoriaus kristalinė forma ir jos gavimo būdas - Google Patents
Androgeno receptorių inhibitoriaus kristalinė forma ir jos gavimo būdasInfo
- Publication number
- LT3348546T LT3348546T LTEP16843560.0T LT16843560T LT3348546T LT 3348546 T LT3348546 T LT 3348546T LT 16843560 T LT16843560 T LT 16843560T LT 3348546 T LT3348546 T LT 3348546T
- Authority
- LT
- Lithuania
- Prior art keywords
- preparation
- crystalline form
- androgen receptor
- receptor inhibitor
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510574141 | 2015-09-10 | ||
| CN201610073458 | 2016-02-02 | ||
| PCT/CN2016/096381 WO2017041622A1 (zh) | 2015-09-10 | 2016-08-23 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3348546T true LT3348546T (lt) | 2020-07-27 |
Family
ID=58240573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP16843560.0T LT3348546T (lt) | 2015-09-10 | 2016-08-23 | Androgeno receptorių inhibitoriaus kristalinė forma ir jos gavimo būdas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10150739B2 (lt) |
| EP (1) | EP3348546B1 (lt) |
| JP (1) | JP6843116B2 (lt) |
| KR (1) | KR20180048939A (lt) |
| CN (1) | CN107001284B (lt) |
| AU (1) | AU2016318700B2 (lt) |
| BR (1) | BR112018003258A2 (lt) |
| CA (1) | CA2996674A1 (lt) |
| CY (1) | CY1123027T1 (lt) |
| DK (1) | DK3348546T3 (lt) |
| ES (1) | ES2794568T3 (lt) |
| HR (1) | HRP20200852T1 (lt) |
| HU (1) | HUE050459T2 (lt) |
| LT (1) | LT3348546T (lt) |
| MX (1) | MX2018002759A (lt) |
| PL (1) | PL3348546T3 (lt) |
| PT (1) | PT3348546T (lt) |
| RS (1) | RS60448B1 (lt) |
| RU (1) | RU2018109121A (lt) |
| SI (1) | SI3348546T1 (lt) |
| TW (1) | TWI708764B (lt) |
| WO (1) | WO2017041622A1 (lt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60448B1 (sr) | 2015-09-10 | 2020-07-31 | Jiangsu Hengrui Medicine Co | Kristalni oblik inhibitora receptora androgena i postupak njegovog dobijanja |
| CN112300076B (zh) * | 2017-12-13 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101048381A (zh) * | 2004-09-09 | 2007-10-03 | 中外制药株式会社 | 新型四氢咪唑衍生物及其用途 |
| PL2444085T3 (pl) | 2005-05-13 | 2015-07-31 | Univ California | Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka |
| WO2010118354A1 (en) | 2009-04-09 | 2010-10-14 | Medivation Prostate Therapeutics, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof |
| CN103958480B (zh) | 2012-09-04 | 2016-04-06 | 上海恒瑞医药有限公司 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
| BR112015005404A2 (pt) * | 2012-09-11 | 2017-08-22 | Dr Reddys Laboratories Ltd | Formas polimórficas de enzalutamida e sua preparação |
| CN104356068A (zh) * | 2014-10-30 | 2015-02-18 | 杭州新博思生物医药有限公司 | 恩杂鲁胺新晶型及其制备方法 |
| RS60448B1 (sr) | 2015-09-10 | 2020-07-31 | Jiangsu Hengrui Medicine Co | Kristalni oblik inhibitora receptora androgena i postupak njegovog dobijanja |
-
2016
- 2016-08-23 RS RS20200617A patent/RS60448B1/sr unknown
- 2016-08-23 JP JP2018508712A patent/JP6843116B2/ja active Active
- 2016-08-23 KR KR1020187009184A patent/KR20180048939A/ko not_active Application Discontinuation
- 2016-08-23 RU RU2018109121A patent/RU2018109121A/ru unknown
- 2016-08-23 US US15/757,652 patent/US10150739B2/en active Active
- 2016-08-23 PT PT168435600T patent/PT3348546T/pt unknown
- 2016-08-23 CN CN201680003850.4A patent/CN107001284B/zh active Active
- 2016-08-23 BR BR112018003258-1A patent/BR112018003258A2/pt not_active Application Discontinuation
- 2016-08-23 LT LTEP16843560.0T patent/LT3348546T/lt unknown
- 2016-08-23 ES ES16843560T patent/ES2794568T3/es active Active
- 2016-08-23 CA CA2996674A patent/CA2996674A1/en active Pending
- 2016-08-23 EP EP16843560.0A patent/EP3348546B1/en active Active
- 2016-08-23 DK DK16843560.0T patent/DK3348546T3/da active
- 2016-08-23 PL PL16843560T patent/PL3348546T3/pl unknown
- 2016-08-23 MX MX2018002759A patent/MX2018002759A/es unknown
- 2016-08-23 WO PCT/CN2016/096381 patent/WO2017041622A1/zh active Application Filing
- 2016-08-23 SI SI201630801T patent/SI3348546T1/sl unknown
- 2016-08-23 AU AU2016318700A patent/AU2016318700B2/en not_active Ceased
- 2016-08-23 HU HUE16843560A patent/HUE050459T2/hu unknown
- 2016-09-07 TW TW105128891A patent/TWI708764B/zh active
-
2020
- 2020-05-26 HR HRP20200852TT patent/HRP20200852T1/hr unknown
- 2020-06-09 CY CY20201100522T patent/CY1123027T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2996674A1 (en) | 2017-03-16 |
| EP3348546B1 (en) | 2020-04-29 |
| US10150739B2 (en) | 2018-12-11 |
| HUE050459T2 (hu) | 2020-12-28 |
| CN107001284B (zh) | 2019-11-22 |
| AU2016318700B2 (en) | 2020-05-07 |
| PL3348546T3 (pl) | 2020-09-21 |
| US20180244628A1 (en) | 2018-08-30 |
| TWI708764B (zh) | 2020-11-01 |
| CN107001284A (zh) | 2017-08-01 |
| PT3348546T (pt) | 2020-05-29 |
| WO2017041622A1 (zh) | 2017-03-16 |
| CY1123027T1 (el) | 2021-10-29 |
| RS60448B1 (sr) | 2020-07-31 |
| BR112018003258A2 (pt) | 2018-09-25 |
| JP2018526364A (ja) | 2018-09-13 |
| RU2018109121A3 (lt) | 2019-12-04 |
| SI3348546T1 (sl) | 2020-09-30 |
| AU2016318700A1 (en) | 2018-04-05 |
| KR20180048939A (ko) | 2018-05-10 |
| JP6843116B2 (ja) | 2021-03-17 |
| RU2018109121A (ru) | 2019-10-10 |
| MX2018002759A (es) | 2018-08-01 |
| ES2794568T3 (es) | 2020-11-18 |
| DK3348546T3 (da) | 2020-07-06 |
| HRP20200852T1 (hr) | 2020-08-21 |
| TW201713628A (zh) | 2017-04-16 |
| EP3348546A1 (en) | 2018-07-18 |
| EP3348546A4 (en) | 2019-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255738A (en) | A new crystalline form of lenbatinib mesylate and a process for its preparation | |
| GB201514756D0 (en) | Compound and method of use | |
| IL284005A (en) | Glucocorticoid receptor inhibitors | |
| GB201514760D0 (en) | Compounds and method of use | |
| SI3380554T1 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| HK1256860A1 (zh) | 喹唑啉衍生物的晶體及其製備方法 | |
| HK1244274A1 (zh) | C21h22ci2n4o2的晶型 | |
| IL253186B (en) | A new crystalline form of a benzaimidazole derivative and a method for its preparation | |
| PL3327012T3 (pl) | Krystaliczne postacie bilastyny i sposoby ich wytwarzania | |
| HK1252057A1 (zh) | 新穎的使用方法和組合物 | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| HK1258438A1 (zh) | 2-巰基苯並噻唑的製備方法 | |
| HUE055891T2 (hu) | A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| RS60448B1 (sr) | Kristalni oblik inhibitora receptora androgena i postupak njegovog dobijanja | |
| HK1252375A1 (zh) | 喹唑啉衍生物的晶體及其製備方法 | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| IL270937A (en) | Crystalline forms of saltalicib |